Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) Sees Significant Decline in Short Interest

Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 81,400 shares, a decline of 19.2% from the November 30th total of 100,700 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days.

Newron Pharmaceuticals Price Performance

Shares of NWPHF stock remained flat at $9.36 during trading hours on Friday. Newron Pharmaceuticals has a 52-week low of $9.10 and a 52-week high of $12.00. The company has a 50 day moving average price of $9.36 and a 200-day moving average price of $9.92.

Newron Pharmaceuticals Company Profile

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea.